Sector Experts

Robin Davison

Edison Investment Research




Recent Quotes

"The central element of ADXN's revised strategy is to advance its clinical-stage candidates." (3/5/13) Addex Therapeutics - Robin Davison, Edison Investment Research More >

"ADXN's coming phase II studies could catalyze a significant increase in value." (1/4/12) Addex Therapeutics - Robin Davison, Edison Investment Research More >

"ADXN has the potential to generate high-value product opportunities." (9/6/11) Addex Therapeutics - Robin Davison, Edison Investment Research More >

"ADXN's new CEO has experience and a strong track record." (8/16/11) Addex Therapeutics - Robin Davison, Edison Investment Research More >



Due to permission requirements, not all quotes are shown.